Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology
You may also be interested in...
AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.
Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.